Regeneron is a biotechnology company that develops medications using monoclonal antibodies and other biologic drugs. These treatments address conditions like eye disorders, high cholesterol, and COVID-19.
| Treatment | Condition Treated |
|---|---|
| Eylea | Wet age-related macular degeneration (AMD) |
| Praluent | High cholesterol |
| Kevzara | Rheumatoid arthritis |
| REGEN-COV | COVID-19 |
Some people confuse Regeneron's treatments with vaccines. However, Regeneron's REGEN-COV is a monoclonal antibody therapy, not a vaccine. Vaccines train the immune system to recognize and fight off pathogens, while monoclonal antibodies provide immediate, short-term protection.
During the COVID-19 pandemic, Regeneron's REGEN-COV was used to treat high-risk patients who had contracted the virus. The treatment helped reduce viral load and improve symptoms. According to a study published in the New England Journal of Medicine, REGEN-COV reduced the risk of hospitalization or death by 70% in high-risk patients.
Regeneron's medications play a important role in treating various conditions through new biologic drugs. From eye disorders to COVID-19, these treatments offer targeted solutions for patients in need.